Sector News

Stryker announces organizational changes: Lonny J. Carpenter to retire

April 4, 2018
Life sciences

Stryker Corporation announced today that after 30 years of distinguished service, Lonny Carpenter, Group President, Global Quality and Business Operations has notified the Company of his intent to retire on March 31, 2019.

Mr. Carpenter will transfer his responsibility for Global Quality and Operations to Viju Menon, as outlined below, and retain responsibilities for our regional business operations outside of the U.S. and Asia-Pacific. He will also remain involved with our Cost Transformation for Growth program.

Mr. Carpenter began his career with Stryker in 1989 at the Instruments division where he excelled in various manufacturing and operations roles. He then proceeded to take on numerous operations and commercial business roles across the Company, including President of Medical and Group President, Instruments and Medical. In 2011, he became Group President, Global Quality and Operations and in 2014, his role was expanded to include responsibility for commercial business operations in Europe, Middle East, Africa, Canada, and Latin America.

“We are grateful for Lonny’s many contributions to Stryker’s growth and globalization efforts over the last three decades. He has been the key architect of numerous change initiatives, including our Quality Program, the establishment of our Trans-Atlantic Operating Model and Cost Transformation for Growth. He is a master collaborator and embodies our culture and values. I wish Lonny and his family all the best on his retirement,” said Kevin A. Lobo, Chairman and Chief Executive Officer.

Viju Menon will be joining Stryker as Group President, Global Quality and Operations, effective April 30, 2018. He will be responsible for running our quality, manufacturing, procurement and logistics organizations. He will work closely with Lonny to help ensure a smooth transition. “I am pleased that Viju will be joining the Stryker Leadership Team. His vast experience and technology background will complement our team and help drive Stryker’s continued growth,” said Mr. Lobo.

Mr. Menon joins us from Verizon where he served as Chief Supply Chain Officer, driving significant transformations in global sourcing and operations across all business units. Previously, in his career with Intel Corporation, Viju progressed through various leadership roles in Technology and Manufacturing and served as Head of Supply Planning Operations across Intel’s global factory network.

Mr. Menon earned dual graduate degrees (MBA and M.S. in Electrical Engineering) from the Massachusetts Institute of Technology’s Leaders for Global Operations Program. He also earned a graduate degree (M.S.E. in Computer Science Engineering) from the University of Michigan.

Source: Stryker

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).